Trials / Completed
CompletedNCT04570267
Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Study CSL324\_1003 is a single center, randomized, double-blind, placebo-controlled study designed to characterize and compare the PK properties and safety of a single subcutaneous dose of CSL324 in healthy Japanese and White subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CSL324 | Sterile solution of recombinant anti G-CSF receptor monoclonal antibody for injection |
| DRUG | Placebo | Sterile solution of CSL324 formulation buffer for injection |
Timeline
- Start date
- 2020-10-08
- Primary completion
- 2021-11-17
- Completion
- 2021-12-09
- First posted
- 2020-09-30
- Last updated
- 2022-10-04
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT04570267. Inclusion in this directory is not an endorsement.